Aspirin Versus Clopidogrel in Chronic Coronary Syndrome in Arabian Gulf Countries
ConditionChronic Coronary Syndrome
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorKhalid F Alhabib
About this trial
Determine the long-term efficacy of clopidogrel compared with aspirin in reducing heart or brain attacks in patients with stable heart disease
Eligibility criteria
Qualifiers
Age ≥18 years.
Significant coronary artery disease (coronary angiogram documentation of Left Main artery lesion ≥50% and/or lesion(s) ≥70% in other coronary arteries, and/or FFR<0.8 or iFR<0.9).
Completed at least 6 months post ACS (regardless of the bleeding risk, anti-platelet strategy, revascularization strategy "PCI, CABG, or conservative medical management only", before randomization).
Agreement to give written informed consent.
Disqualifiers
History of hypersensitivity to aspirin or clopidogrel.
Presence of non-cardiac comorbidity with life expectancy ≤2 years from randomization.
Plan for surgery or intervention which requires stopping antiplatelet agents ≥3 months.
Females with childbearing potential or breast-feeding.
Trial design
Treatments tested in this trial
- Aspirin
- Clopidgrel 75 mg daily
Treatment groups
6,740 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Khalid F Alhabib
Lead sponsor
Saudi Heart Association
Sponsor institution
Source ClinicalTrials.gov